| Literature DB >> 26275476 |
Jody C Chuang1, Joel W Neal2, Xiao-Min Niu3, Heather A Wakelee4.
Abstract
Tyrosine kinase inhibitors (TKIs) against targetable mutations such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are highly effective in treating advanced stage lung cancers harboring such mutations. Questions remain, however, about whether these agents can improve cure rates for early stage lung cancers in the adjuvant setting. Here, we examine the current data and ongoing trials addressing this issue.Entities:
Keywords: Adjuvant; Anaplastic lymphoma kinase (ALK); Epidermal growth factor receptor (EGFR); Non-small cell lung cancer (NSCLC); Tyrosine kinase inhibitors (TKI)
Mesh：
Substances：
Year: 2015 PMID： 26275476 DOI： 10.1016/j.lungcan.2015.07.016
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705